



Policy Updates - Third Quarter 2023

NEW DRUG SPECIFIC POLICIES *Effective 10/1/2023*

Akeega (niraparib and abiraterone acetate) tablets	Izervay (avacincaptad pegil intravitreal solution)	Vyjuvek (beremagene geoerpavec-svdt)
Beyfortus (nirsevimab-alip)	Lantidra (donislecel-jujn)	Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)
Columvi (glofitamab-gxbm)	Leqembi (lecanemab-irmb) State Products <i>(effective 7/6/23)</i>	Xacduro (sulbactam-durlobactam)
Elevidys (delandistrogene moxeparvovec-rokl)	Lodoco (colchicine) tablets	Ycanth (cantharidin) topical solution
Elevidys (delandistrogene moxeparvovec-rokl) – State Plans	Roctavian (valoctocogene roxaparvovec-rvox)	Zurzuvae (zuranolone) capsules
Elfabrio (pegunigalsidase alpha-iwxj)	Rystiggo (rozanolixizumab-noli)	
Elrexio (elranatamab-bcmm)	Talvey (talquetamab-tgvs)	
Epkinly (epcoritamab-bysp) Subcutaneous Injection	Vanflyta (quizartinib)	
	Veozah (fezolinetant)	

EXISTING DRUG SPECIFIC POLICIES WITH CLINICAL CHANGES *Effective 10/1/2023*

Ayvakit	Imbruvica	Saphnelo
Biologic Drugs for Auto-Immune Diseases (BDAID) – Self Administered policy	Lampit	Sucraid (sacrosidase) Oral Solution
Bylvay	Leqembi (lecanemab-irmb) FEHB	Synagis
Cyclosporine Ophthalmic Drops – Applies to Cequa, Restasis and Vevye	Leqvio	Talzenna
Gavreto	Lonsurf	Weight Loss Medications
	Lynparza	Xpovio
	Prevymis	Zinplava

EXISTING DRUG SPECIFIC POLICIES WITH ADMINISTRATIVE CHANGES *Effective 10/1/2023*

Amvuttra	Growth Hormone – State Plans	Leqembi (lecanemab-irmb)
Daliresp (roflumilast)	Growth Hormone	Lotronex
Epoetin Alpha	Intra-articular Injections of Hyaluronate Products	Mayzent
Fintepla	Invega Trinza	Nexviazyme
		Pegfilgrastim (Applies to Fulphila, Fylnetra, Neulasta,

Nyvepria, Stimufend, Udenyca, and Ziextenzo)	Sivextro (tedizolide phosphate)	Tezpire
Radicava	Spravato	Tysabri
Ranibizumab Injection	Tecvayli™ (teclistamab-cqyv)	Xadago
Rolvedon	Testosterone Intramuscular Injection	Zolgensma

EXISTING DRUG SPECIFIC POLICIES WITH ADMINISTRATIVE CHANGES DUE TO MEDICAID CARVE-OUT

Ampyra	Lybalvi	Sunosi
Aromatase Inhibitor	Mavenclad	Symlin
Chenodal Step therapy	Mayzent – Child Health Plus	Symproic
Cholbam	Mycapssa	Tacrolimus Extended-release – Applies to Astagraf XL and Envarsus XR
Corlanor	Myfembree	Tavalisse
Cumulative Opioid Morphine Milligram Equivalent Dosing (MME) Edit	Nayzilam	Testosterone Oral Buccal
Cuvrior	Neupro	Thrombopoietin Receptor Agonist
Dojolvi	Nitrofurantoin Oral Suspension	Tracleer
Duobrii	Nuplazid	Tymlos
Enspryng	Ocaliva	Uceris
Epidiolex	Onureg	Upneeq
Erlotinib	Orkambi	Verkazia
Evrysdi	Ovulation Enhancing Drugs – Essential Plan	Viberzi
Gimoti	Palyngiq	Vtama
Hemangeol	Panretin	Welireg
Inqovi	Procsybi	Winlevi
Jynarque	Ravicti	Xifaxan
Kerendia	Rezurock	Xyrem
Kesimpta	Rocklatan	Xywav
Lucemyra	Somavert	Yonsa
Lumakras		

EXISTING DRUG SPECIFIC POLICIES REVIEW ONLY/NO CHANGES

Akynzeo Injection	Evenity	Ryplazim
Aranesp	Gender Dysphoria Treatment – Commercial plans	Spravato Nasal Spray - Medisource
Austedo and Austedo XR	GnRH Receptor Antagonist Policy for Infertility	Step Therapy Exception
CGRP Receptor Antagonist for Prophylaxis	In Vitro Fertilization (IVF) and Fertility Preservation	Sylvant
CGRP Receptor Antagonist for Acute Treatment	Lumizyme	Testosterone Implantable
Children’s Behavioral Health Prescriber Policy	Prialt	Uplinza
Dovato	Purified Proteinase Inhibitor	Viltepso
	Reclast	Zyprexa Relprev

EXISTING ADMINISTRATIVE POLICIES WITH CHANGES

Application of Tiered Formulary Policy

Drug Utilization Review Policy

EXISTING ADMINISTRATIVE POLICIES REVIEW ONLY/NO CHANGES

Denial Policy	Inter-rater Reliability	Pharmacy Clinical Presentations
Inter-rater Reliability Audit for Pharmacist Reviewers	Pharmacy Audit for Physician Reviewers	Prior Authorization Review
	Pharmacy Authorization Timeliness Policy	

POLICIES TO BE ARCHIVED

Kynmobi	Sublocade	Vegzelma
---------	-----------	----------

PBD NEW DRUG SPECIFIC POLICIES *Effective 10/1/2023*

Cosela

Sprycel

PBD EXISTING DRUG SPECIFIC POLICIES WITH CLINICAL CHANGES *Effective 10/1/2023*

Weight Loss Medication

Weight Loss Medication for the Labor-Management Healthcare Fund

PBD EXISTING DRUG SPECIFIC POLICIES WITH ADMINISTRATIVE CHANGES

Xifaxan

PBD EXISTING DRUG SPECIFIC POLICIES REVIEW ONLY/NO CHANGES

Viberzi

Magellan RX Management Drug Specific Policies Effective 8/1/2023

Darzalex® (daratumumab) IV	Darzalex Faspro® (daratumumab and hyaluronidase-fihj) SQ	Imfinzi® (durvalumab) Perjeta® (pertuzumab)
----------------------------	--	--

Magellan RX Management Drug Specific Policies for Expansion Effective 9/1/2023

Cimerli (Ranibizumab policy)	Rolvedon (eflapegrastim- xnst)	Vegzelma (Bevacizumab policy)
Fynetra (Pegfilgrastim policy)	Stimufend (Pegfilgrastim policy)	

Existing Magellan RX Management Drug Specific Custom Policy Updates Effective 7/1/2023

Colony Stimulating Factors: Filgrastim (Neupogen®); Filgrastim-aafi (Nivestym™); Filgrastim-sndz (Zarxio®); Filgrastim-ayow (Releuko®); Tbo-Filgrastim (Granix®)

Colony Stimulating Factors – Pegfilgrastim:Neulasta®; Fulphila®; Udenyca®; Ziextenzo®; Nyvepria™; Fynetra®; Stimufend®

Existing Magellan RX Management Drug Specific Custom Policy Updates Effective 8/1/2023

Onpattro

Paclitaxel Albumin Bound: Abraxane; Paclitaxel Albumin-Bound

Existing Magellan RX Management Drug Specific Custom Policy Updates Effective 10/1/2023

Saphnelo® (anifrolumab-fnia)

Existing Magellan RX Management Drug Specific Policies w/Clinical Changes *Effective 7/28/23

Medical PA Only

Anti-Inhibitor Coagulant	Factor VIII_vWF	Keytruda
Complex	Factor X	Libtayo
Anti-Inhibitor_Ab	Factor XIII	Perjeta
Bavencio	Factor XIIIa_subunit	Ryplazim
Factor IX	Imfinzi	Tecentriq
Factor VIIa	Ixempra	Vectibix
Factor VIII	Jemperli	VWF

Pharmacy PA Only

Cosentyx	Zejula
----------	--------

Existing Magellan RX Management Drug Specific Policies w/Clinical Changes *Effective 8/25/2023

Medical PA Only

Abraxane (Paclitaxel_Albumin-Bound)	Erbitux	Perjeta
Adcetris	Gazyva	Rituximab_IV
Bendamustine	Imfinzi	Trastuzumab_IV
Bevacizumab_ONCO	Kadcyla	Yervoy
Cyramza	Kyprolis	Yondelis
Enhertu	Opdivo	Vyxeos
	Pemetrexed	

Pharmacy PA Only

Alecensa	Lonsurf	Tazverik
Ayvakit	Lynparza	Tibsovo
Bosulif	Nerlynx	Ukoniq
Copiktra	Odomzo	Vitrakvi
Daurismo	Piqray	Vizimpro
Fotivda	Rozlytrek	Votrient
Iclusig	Scemblix	Xtandi
Idhifa	Sprycel	Zolinza
Inlyta	Talzenna	Zydelig
Iressa	Tasigna	

PSCE only (effective 8/1/23)

Injectafer

Existing Magellan RX Management Drug Specific Policies w/Clinical Changes *Effective 9/22/2023

Medical PA Only

Entyvio	Jemperli	Spinraza
Ilaris	Pemetrexed	Stelara
Ilumya	Sandostatin_LAR	Xipere

Pharmacy PA Only

Cosentyx	Ibrance	Onureg
Evrysdi	Inqovi	Verzenio

Medical/Pharmacy

Orencia